Answers are grounded in this paper and cite their sources.
Retrospective audit evaluates percutaneous transhepatic biliary drainage impact on outcomes in malignant hilar biliary obstruction, suggesting re-evaluation of its clinical use.
Background Decompression of malignant biliary obstruction is important for quality of life and potential chemotherapy (CTx). PTBD is an alternative when endoscopic stenting with ERCP is not possible. In MHBO, PTBD is the preferred intervention as multiple branches may be obstructed rendering ERCP stenting suboptimal. Aims Assess the impact of PTBD for MHBO on patient outcomes and compare them to management of extrahepatic obstruction. Methods Retrospective chart audit of all patients diagnosed with cholangiocarcinoma (CCA) at the University of Alberta Hospital from 07/2023-06/2024. Primary outcome was a reduction of the bilirubin to < 30 µmol/L. Secondary outcomes were successful initiation and completion of CTx, procedural complications, re-interventions, hospital length of stay (HLOS), and mortality. Results 30 pts (17 M), median age of 70±10 yrs (52-94 yrs) presented with CCA. Location of CCA was intrahepatic in 9, hilar in 13, and extrahepatic in 8 pts. No pts with intrahepatic CCA underwent PTBD and were not included in this review. We compared pts with MHBO and those with extrahepatic CCA (Table). Conclusions The primary outcome was achieved with PTBD in 62% pts with MHBO but significant complications requiring re-intervention precluded optimal CTx, and were associated with a longer HLOS and shorter survival. Further inquiry into cost implications, and assessment of PTBD as standard of care in pts with MHBO is required.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: